Gabapentin Capsule
Product Images NDC 82868-109

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82868-109). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (82868 109 30 Rev A 06 26.pdf)

Gabapentin Capsules USP 300 mg label showing packaging details for 30 capsules. The label indicates Rx only, storage instructions between 20°-25°C, and warnings to keep out of reach of children and store in the original container. Labeler is Northwind Health Company, LLC, with NDC 82868-109-30.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula calculation for creatinine clearance (CLCr) that adjusts for age, weight, and serum creatinine, including a multiplicative factor for female patients. The equation is presented in a text format showing the variables and constants involved.*

FDA Label Image

Structure (Gabapentin Fig 5)

Chemical structure diagram of gabapentin showing its cyclohexane ring and attached amino and carboxyl functional groups.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin treatment shows a decreasing pain score trend, while placebo remains relatively constant.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis indicates mean pain scores, with Gabapentin groups showing a greater reduction in pain compared to placebo.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) treatment groups in two studies. Study 1 shows 12% responders for placebo and 29% for gabapentin 3600 mg. Study 2 shows 14% responders for placebo, 32% for gabapentin 1800 mg, and 34% for gabapentin 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A chart showing the percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis for three studies labeled a, b, and c. Data points for each study are plotted at various doses ranging from 600 mg to 1800 mg, illustrating differences in outcomes by dose across the studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.